ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
The studies will evaluate bempedoic acid alone and in combination with ezetimibe in pediatric patients with heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). The phase III studies are expected to begin later in 2025. Esperion markets bempedoic acid as Nexletol and Nexlizet for treating elevated LDL-C (bad cholesterol) and cardiovascular risk reduction. Nexlizet is a combination of bempedoic acid and ezetimibe. Two separate phase III studies, namely — CLEAR Path 2 (in children with HeFH) and CLEAR Path 3 (in children with HoFH), will evaluate the safety and efficacy of bempedoic acid with and without ezetimibe in children with HeFH or HoFH and LDL-C =130 mg/dL who are on a protocol
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences (GILD) Stock Drops Despite Market Gains: Important Facts to Note [Yahoo! Finance]Yahoo! Finance
- Is VanEck Morningstar Wide Moat ETF (MOAT) a Strong ETF Right Now? [Yahoo! Finance]Yahoo! Finance
- Health Care Roundup: Market Talk [Yahoo! Finance]Yahoo! Finance
- Health Care Roundup: Market Talk [Yahoo! Finance]Yahoo! Finance
- Buy 3 U.S. Giants Flying High Year to Date Defying Severe Volatility [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/11/25 - Beat
GILD
Sec Filings
- 3/20/25 - Form 3
- 3/18/25 - Form 4
- 3/17/25 - Form 144
- GILD's page on the SEC website